Cancer whole exome sequencing (WES)
Whole exome sequencing is a technique that uses probe hybridization to enrich exon regions of DNA sequences. High-throughput sequencing technology following exon enrichment identifies genetic mutations associated with protein dysfunction. Compared with whole genome sequencing, WES is more cost-effective and efficient.
1) Direct sequencing of protein-coding sequences to identify variations that affect protein function;
2) In-depth sequencing that can identify both common variations and rare variations with frequencies lower than 1%;
3) Exome sequencing, which accounts for only 1% of the genome, effectively reduces the cost and turnaround time.
• Sample requirement
• Sample types: DNA samples;
• Sample amount: >=1.0 ug DNA (extracted from fresh or frozen samples);
• >= 1.5 ug DNA (extracted from FFPE samples);
• Sample concentration: >=20 ng/ul;
• Capture platforms: Agilent SureSelect Kit;
• Sequencing strategy: HiSeq PE150;
• Sequencing depth: tumor carcinoma tissue (200 x), normal tissue/blood samples (100x);
• Turnaround time: 42 days.